Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ABUS 
Arbutus Biopharma Corp (ABUS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: ABUS (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $5.25
1 Year Target Price $5.25
| 2 | Strong Buy |
| 1 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 23.03% | Avg. Invested days 36 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 703.54M USD | Price to earnings Ratio - | 1Y Target Price 5.25 |
Price to earnings Ratio - | 1Y Target Price 5.25 | ||
Volume (30-day avg) 4 | Beta 0.86 | 52 Weeks Range 2.71 - 4.72 | Updated Date 08/29/2025 |
52 Weeks Range 2.71 - 4.72 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.29 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-08-06 | When - | Estimate -0.04 | Actual 0.01 |
Profitability
Profit Margin - | Operating Margin (TTM) 17.81% |
Management Effectiveness
Return on Assets (TTM) -21.01% | Return on Equity (TTM) -52.82% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 606535210 | Price to Sales(TTM) 45.64 |
Enterprise Value 606535210 | Price to Sales(TTM) 45.64 | ||
Enterprise Value to Revenue 39.34 | Enterprise Value to EBITDA -5.64 | Shares Outstanding 191699008 | Shares Floating 126049560 |
Shares Outstanding 191699008 | Shares Floating 126049560 | ||
Percent Insiders 21.87 | Percent Institutions 62.59 |
Upturn AI SWOT
Arbutus Biopharma Corp
Company Overview
History and Background
Arbutus Biopharma Corp (formerly Tekmira Pharmaceuticals) was founded in 2003. Initially focused on RNAi delivery technology, it shifted its focus to developing a functional cure for chronic Hepatitis B virus (HBV) infection. Milestones include licensing agreements with pharmaceutical companies and the development of multiple HBV drug candidates.
Core Business Areas
- HBV Therapies: Arbutus focuses on developing therapeutics for chronic HBV infection. Their pipeline includes RNAi therapeutics, capsid inhibitors, and PD-L1 inhibitors.
Leadership and Structure
The leadership team includes the President and CEO, CFO, and Chief Scientific Officer. The organizational structure is typical of a biotech company, with departments dedicated to research and development, clinical trials, regulatory affairs, and finance.
Top Products and Market Share
Key Offerings
- AB-729 (RNAi therapeutic): AB-729, now licensed to Antios, targets the production of all HBV viral proteins and HBsAg. As a research and clinical-stage asset it does not generate revenue for Arbutus at this time, but milestone and royalty payments are expected. Competitors include Aligos Therapeutics, Assembly Biosciences, and Vir Biotechnology (offering combination therapies). The total market for HBV therapies is significant, with a high unmet need for functional cures.
- AB-101 (PD-L1 inhibitor): AB-101 is an oral PD-L1 inhibitor in development for chronic hepatitis B (HBV) infection. As a research and clinical-stage asset it does not generate revenue. Competitors include large pharma companies developing immuno-oncology therapies, and companies developing HBV-specific immunotherapies.
Market Dynamics
Industry Overview
The pharmaceutical industry is competitive, with a growing focus on chronic viral infections. Hepatitis B treatment market includes nucleos(t)ide analogs which suppress viral replication but rarely lead to a functional cure. The demand for new and innovative therapies for chronic Hepatitis B with higher success rates is significant.
Positioning
Arbutus is positioned as a specialist in developing functional cures for chronic HBV infection. Their competitive advantage lies in their expertise in RNAi technology and their diverse pipeline of drug candidates.
Total Addressable Market (TAM)
The global hepatitis B therapeutics market is estimated to be in the billions of dollars. Arbutus is positioned to capture a significant share of this market with successful development and commercialization of their HBV therapies.
Upturn SWOT Analysis
Strengths
- Strong intellectual property position in HBV therapies
- Experienced management team
- Diverse pipeline of drug candidates targeting different aspects of the HBV lifecycle
- Collaboration with Antios for AB-729 development
- Cash and cash equivalents of $136.1 million as of March 31, 2024
Weaknesses
- Dependence on successful clinical trial outcomes
- High cash burn rate
- Reliance on partnerships for late-stage development and commercialization
- Limited resources compared to large pharmaceutical companies
Opportunities
- Successful development and commercialization of their HBV therapies
- Partnerships with other pharmaceutical companies to expand their pipeline
- Acquisition by a larger pharmaceutical company
- Expansion into other viral diseases
Threats
- Clinical trial failures
- Competition from other pharmaceutical companies
- Regulatory hurdles
- Patent challenges
- Changes in the healthcare landscape
Competitors and Market Share
Key Competitors
- Gilead Sciences (GILD)
- Assembly Biosciences (ASMB)
- Vir Biotechnology (VIR)
Competitive Landscape
Arbutus faces intense competition from larger pharmaceutical companies with more resources. Their success depends on the differentiation and efficacy of their drug candidates.
Growth Trajectory and Initiatives
Historical Growth: Arbutus's growth has been dependent on successful clinical trial results and partnerships, which are inherently unpredictable.
Future Projections: Analyst projections vary widely, but hinge on the success of their HBV drug candidates. Future revenue streams are projected from milestone payments and royalties from AB-729 (licensed to Antios).
Recent Initiatives: Arbutus is focused on advancing their HBV drug candidates through clinical trials, securing partnerships, and protecting their intellectual property.
Summary
Arbutus Biopharma is a clinical-stage biopharmaceutical company focusing on developing a functional cure for chronic HBV infection. It is working on several therapeutic candidates in this area. ABUS has a strong intellectual property position and experienced management team, but the company is also dependent on clinical trial outcomes. This, together with competitive pressure, impacts the company's future performance.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Arbutus Biopharma Corp. SEC Filings
- Arbutus Biopharma Corp. Investor Relations
- Third-party market research reports
- Analyst estimates
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Financial data and market share estimates are subject to change. Please conduct your own due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Arbutus Biopharma Corp
Exchange NASDAQ | Headquaters Warminster, PA, United States | ||
IPO Launch date 2015-08-03 | President, CEO & Chairman Ms. Lindsay Androski J.D., M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 44 | Website https://www.arbutusbio.com |
Full time employees 44 | Website https://www.arbutusbio.com | ||
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 1 and phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.